Disitertide (TFA)

ArtNr	HY-P0118A-1mg
Hersteller	MedChem Express
Menge	1 mg
Quantity options	100 mg 10 mg 1 ea 1 mg 25 mg 50 mg 5 mg
Kategorie	Peptides & Proteins Peptides
Typ	Peptides
Specific against	other
Citations	Funct Integr Genomics. 2024 Jul 12;24(4):123. Int Immunopharmacol. 2024 Aug 21:141:112778. Acta Histochem. 2023 Feb;125(2):152010. Cancer Manag Res. 2018 Oct 10;10:4459-4470. Cell Death Differ. 2021 Jan;28(1):219-232. Cells. 2019 Jun 25;8(6):635. Dig Dis Sci. 2020 Jul 15. Eur Rev Med Pharmacol Sci. 2019 Aug;23(3 Suppl):9-16. Front Immunol. 2017 Feb 3;8:91. Int J Mol Med. 2019 May;43(5):2212-2220. J BUON. 2021; 26(2): 435-443. J Exp Clin Cancer Res. 2021 Feb 9;40(1):62. Oncogene. 2019 Jun;38(23):4637-4654. Dig Dis Sci. 2025 Mar 4. [1]Cindy Neuzillet, et al. Targeting the TGFβ pathway for cancer therapy. Pharmacol Ther. 2015 Mar;147:22-31. [2]Jun Yang, et al. Upregulation of microRNA‑590 in rheumatoid arthritis promotes apoptosis of bone cells through transforming growth factor‑β1/phosphoinositide 3‑kinase/Akt signaling. Int J Mol Med. 2019 May;43(5):2212-2220. [3]Wanming He, et al. MSC-regulated lncRNA MACC1-AS1 promotes stemness and chemoresistance through fatty acid oxidation in gastric cancer. Oncogene. 2019 Jun;38(23):4637-4654. [4]Shan Shan Qiu, et al. Effect of P144® (Anti-TGF-β) in an "In Vivo" Human Hypertrophic Scar Model in Nude Mice. PLoS One. 2015 Dec 31;10(12):e0144489. [5]Gabriel Gallo-Oller, et al. P144, a Transforming Growth Factor beta inhibitor peptide, generates antitumoral effects and modifies SMAD7 and SKI levels in human glioblastoma cell lines. Cancer Lett. 2016 Oct 10;381(1):67-75.
Smiles	O=C(O)C(F)(F)F.C[C@@H](O)[C@H](N)C(N[C@@H](CO)C(N[C@@H](CC(C)C)C(N[C@@H](CC(O)=O)C(N[C@@H](C)C(N[C@@H](CO)C(N[C@@H]([C@@H](C)CC)C(N[C@@H]([C@@H](C)CC)C(N[C@H](C(N[C@@H](C)C(N[C@@H](CCSC)C(N[C@@H](CCSC)C(N[C@@H](CCC(N)=O)C(N[C@H](C(O)=O)CC(N)=O)=O)=O)=O)=O)=O)CC1=CNC2=CC=CC=C12)=O)=O)=O)=O)=O)=O)=O)=O
ECLASS 10.1	32160409
ECLASS 11.0	32160409
UNSPSC	12352202
Alias	P144 (TFA)
Versandbedingung	Gekühlt
Lieferbar
Manufacturer - Type	Peptides
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Apoptosis; PI3K; TGF-beta/Smad
Shipping Temperature	Blue Ice
Storage Conditions	-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)
Molecular Weight	1580.82 (free acid)
Product Description	Disitertide (P144) TFA is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide TFA is also a PI3K inhibitor and an apoptosis inducer[1][2][3][4][5].
Manufacturer - Research Area	Cancer
Solubility	H2O : < 0.1 mg/mL
Manufacturer - Pathway	Apoptosis; PI3K/Akt/mTOR; Stem Cell/Wnt; TGF-beta/Smad
Clinical information	Phase 2

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-P0118A-1mg-safety-datasheet.pdf